RT Journal Article T1 Serum vascular endothelial growth factor b and metabolic syndrome incidence in the population based cohort Di@bet.es study. A1 Lago-Sampedro, Ana A1 Lhamyani, Said A1 Valdes, Sergio A1 Colomo, Natalia A1 Maldonado-Araque, Cristina A1 Gonzalez-Molero, Inmaculada A1 Doulatram-Gamgaram, Viyey A1 Delgado, Elias A1 Chaves, Felipe J A1 Castaño, Luis A1 Calle-Pascual, Alfonso A1 Franch-Nadal, Josep A1 Rojo-Martinez, Gemma A1 Garcia-Serrano, Sara A1 Garcia-Escobar, Eva K1 Metabolic Syndrome K1 C-Reactive Protein K1 Vascular Endothelial Growth Factor B K1 Obesity, Abdominal K1 Cross-Sectional Studies AB Although vascular endothelial growth factor b (VEGFb) might have an impact on the development of obesity, diabetes and related disorders, the possible relationship between VEGFb serum levels and the incidence of these metabolic complications in humans is still unknown. The aim of our study was to evaluate the association between VEGFb serum levels and the new-onset of metabolic syndrome (MS) and its components in the Spanish adult population after 7.5 years of follow-up. A total of 908 subjects from the Di@bet.es cohort study without MS at cross-sectional stage according to International Diabetes Federation (IDF) or Adult Treatment Panel III (ATP-III) criteria were included. Additionally, five sub-populations were grouped according to the absence of each MS component at baseline. Socio-demographic, anthropometric and clinical data were recorded. The Short Form of International Physical Activity Questionnaire (SF-IPAQ) was used to estimate physical activity. A fasting blood extraction and an oral glucose tolerance test were performed. Serum determinations of glucose, lipids, hsCRP and insulin were made. VEGFb levels were determined and categorized according to the 75th percentile of the variable. New cases of MS and its components were defined according to ATPIII and IDF criteria. A total of 181 or 146 people developed MS defined by IDF or ATP-III criteria respectively. Serum triglyceride levels, hs-CRP and systolic blood pressure at the baseline study were significantly different according to the VEGFb categories. Adjusted logistic regression analysis showed that the likelihood of developing MS and abdominal obesity was statistically reduced in subjects included in the higher VEGFb category. Low serum levels of VEGFb may be considered as early indicators of incident MS and abdominal obesity in the Spanish adult population free of MS, independently of other important predictor variables. PB Nature Publishing Group YR 2022 FD 2022-08-20 LK http://hdl.handle.net/10668/22598 UL http://hdl.handle.net/10668/22598 LA en NO Lago-Sampedro A, Lhamyani S, Valdés S, Colomo N, Maldonado-Araque C, González-Molero I, et al. Serum vascular endothelial growth factor b and metabolic syndrome incidence in the population based cohort Di@bet.es study. Int J Obes (Lond). 2022 Nov;46(11):2013-2020 DS RISalud RD Jul 5, 2025